Metraipolis › archive › dc_98ebf64b83de
Nationwide introduction of HPV vaccine in Zimbabwe 2018-2019: Experiences with multiple cohort vaccination delivery — Europe PMC PMID:36962162
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/36962162
- DOI
- 10.1371/journal.pgph.0000101
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-19T07:36:53.791Z
- SHA-256 of the archived text
65acb5809cc93d4bab884781de89822fced7b9f6379284389f390488c8c84fe7- Stable URL of this page
https://metraipolis.com/documento/dc_98ebf64b83de
How to cite
Nationwide introduction of HPV vaccine in Zimbabwe 2018-2019: Experiences with multiple cohort vaccination delivery — Europe PMC PMID:36962162 — Europe PMC (en), https://europepmc.org/article/MED/36962162 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_98ebf64b83de (Metraipolis archive dc_98ebf64b83de, sha256 65acb5809cc93d4bab884781de89822fced7b9f6379284389f390488c8c84fe7)
BibTeX
@misc{dc98ebf64b83de,
title = {Nationwide introduction of HPV vaccine in Zimbabwe 2018-2019: Experiences with multiple cohort vaccination delivery — Europe PMC PMID:36962162},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/36962162},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_98ebf64b83de; sha256 65acb5809cc93d4bab884781de89822fced7b9f6379284389f390488c8c84fe7},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/36962162. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
The World Health Organization (WHO) recommends the human papillomavirus (HPV) vaccine for girls aged 9-14 years for cervical cancer prevention and encourages vaccinating multiple cohorts in the first year to maximize impact. The HPV vaccine was introduced nationwide in Zimbabwe in 2018 through a 1-week school-based campaign to multiple cohorts (all girls 10-14 years old), followed by a single cohort (grade 5 girls in school and age 10 girls out-of-school) in 2019. During the 2019 campaign, the multiple cohort's second dose was concurrently delivered with the single cohort's first dose. We interviewed national-level key informants, reviewed written materials, and observed vaccination sessions to document HPV vaccine introduction in Zimbabwe and identify best practices and challenges. Key informants included focal persons from government health and education ministries, in-country immunization partners, and HPV Vaccine Strategic Advisory Group members. We conducted a desk review of policy/strategy documents, introduction plans, readiness reports, presentations, and implementation tools. Vaccination sessions were observed in three provinces during the 2019 campaign. Key informants (n = 8) identified high cervical cancer burden, political will, vaccine availability, donor financing, and a successful pilot program as factors driving the decision to introduce the HPV vaccine nationally. The school-based delivery strategy was well accepted, with strong collaboration between health and education sectors and high community demand for vaccine identified as key contributors to this success. Challenges with transitioning from a multiple age-based to single grade- and age-based target population as well as funding shortages for operational costs were reported. Zimbabwe's first multiple cohort, school-based HPV vaccination campaign was considered successful-primarily due to strong collaboration between health and education sectors and political commitment; however, challenges vaccinating overlapping cohorts in the 2019 campaign were observed. Integration with existing health and vaccination activities and continued resource mobilization will ensure sustainability of Zimbabwe's HPV vaccination program in the future. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PLOS global public health, 2022 (prima pubblicazione 2022-04-06). Identificativi: PMID 36962162 · PMCID PMC10021852 · DOI 10.1371/journal.pgph.0000101. Pagina: https://europepmc.org/article/MED/36962162 — https://doi.org/10.1371/journal.pgph.0000101. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-19T07:33:25.543Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.